CN106573042A - 治疗多发性骨髓瘤的药物组合 - Google Patents
治疗多发性骨髓瘤的药物组合 Download PDFInfo
- Publication number
- CN106573042A CN106573042A CN201580042010.4A CN201580042010A CN106573042A CN 106573042 A CN106573042 A CN 106573042A CN 201580042010 A CN201580042010 A CN 201580042010A CN 106573042 A CN106573042 A CN 106573042A
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- compounds
- apply
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462033386P | 2014-08-05 | 2014-08-05 | |
US62/033,386 | 2014-08-05 | ||
PCT/US2015/043825 WO2016022697A1 (en) | 2014-08-05 | 2015-08-05 | Drug combinations to treat multiple myeloma |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106573042A true CN106573042A (zh) | 2017-04-19 |
Family
ID=53836256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580042010.4A Pending CN106573042A (zh) | 2014-08-05 | 2015-08-05 | 治疗多发性骨髓瘤的药物组合 |
Country Status (13)
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
JP6756617B2 (ja) | 2014-02-14 | 2020-09-16 | エグゼリクシス, インコーポレイテッド | N−{4−[(6,7−ジメトキシキノリン−4−イル)オキシ]フェニル}−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法 |
EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
CA2957466C (en) | 2014-08-05 | 2023-10-17 | Exelixis, Inc. | Drug combinations to treat multiple myeloma |
RU2748549C2 (ru) | 2016-04-15 | 2021-05-26 | Экселиксис, Инк. | Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата |
WO2019053611A1 (en) * | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | POLY THERAPY FOR THE TREATMENT OF CANCER |
IL300824A (en) | 2018-01-26 | 2023-04-01 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
TWI770624B (zh) | 2018-06-15 | 2022-07-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
WO2023222946A1 (en) | 2022-05-18 | 2023-11-23 | Fermion Oy | Process for the preparation of cabozantinib |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
CN102812027A (zh) * | 2010-02-03 | 2012-12-05 | 因西特公司 | 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪 |
CN103304552A (zh) * | 2012-03-09 | 2013-09-18 | 广东东阳光药业有限公司 | 取代的吡啶化合物及其使用方法和用途 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6402215B1 (en) * | 1996-05-21 | 2002-06-11 | American Moto Products, Inc. | Vehicle cargo bed extender |
EP2609919A3 (en) | 2003-09-26 | 2014-02-26 | Exelixis, Inc. | c-Met modulators and methods of use |
WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
AU2006231646A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-Met modulators and methods of use |
AU2007334402B2 (en) | 2006-12-14 | 2014-02-13 | Exelixis, Inc. | Methods of using MEK inhibitors |
UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
MX2011005038A (es) | 2008-11-13 | 2011-06-16 | Exelisis Inc | Metodo de preparacion de derivados de quinolina. |
JP2012511017A (ja) | 2008-12-04 | 2012-05-17 | エグゼリクシス, インコーポレイテッド | キノリン誘導体の調製方法 |
TW202241853A (zh) | 2009-01-16 | 2022-11-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
NZ597695A (en) | 2009-07-17 | 2014-05-30 | Exelixis Inc | Crystalline forms of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl} oxy)phenyl]-n’-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
US20130143881A1 (en) | 2010-03-12 | 2013-06-06 | Exelixis, Inc. | Hydrated Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
WO2012009723A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
JP5934204B2 (ja) | 2010-07-16 | 2016-06-15 | エクセリクシス, インク. | C−met調節剤の薬学的組成物 |
WO2012044577A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
EA027476B1 (ru) | 2010-09-27 | 2017-07-31 | Экселиксис, Инк. | Применение n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости |
WO2012044574A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
CN103327979A (zh) | 2010-11-22 | 2013-09-25 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | 治疗癌症的方法 |
KR20200031711A (ko) | 2011-02-10 | 2020-03-24 | 엑셀리시스, 인코포레이티드 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
CN103717221A (zh) | 2011-05-02 | 2014-04-09 | 埃克塞里艾克西斯公司 | 治疗癌症和骨癌疼痛的方法 |
TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
EP2758057B1 (en) | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
JP6208140B2 (ja) | 2011-10-20 | 2017-10-04 | エクセリクシス, インク. | キノリン誘導体の調製プロセス |
EP2776033A1 (en) | 2011-11-08 | 2014-09-17 | Exelixis, Inc. | Dual inhibitor of met and vegf for treating cancer |
CA2863986A1 (en) * | 2012-02-06 | 2013-08-15 | The Regents Of The University Of California | Emp2 regulates angiogenesis in cancer cells through induction of vegf |
WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
EP2892532B1 (en) | 2012-09-07 | 2019-02-13 | Exelixis, Inc. | Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma |
US20140221372A1 (en) | 2013-02-06 | 2014-08-07 | GlaxoSmithKline Intellectual Property (NO 2.) Limited | Method of administration and treatment |
CN105121412B (zh) | 2013-03-15 | 2019-07-12 | 埃克塞里艾克西斯公司 | N-(4-{[6,7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n′-(4-氟苯基)环丙烷-1,1-二甲酰胺的代谢物 |
JP2016515628A (ja) | 2013-04-04 | 2016-05-30 | エグゼリクシス, インコーポレイテッド | 癌を治療するための複合薬 |
US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
JP6756617B2 (ja) | 2014-02-14 | 2020-09-16 | エグゼリクシス, インコーポレイテッド | N−{4−[(6,7−ジメトキシキノリン−4−イル)オキシ]フェニル}−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法 |
EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
MX2016013600A (es) | 2014-04-25 | 2017-04-27 | Exelixis Inc | Método para tratar adenocarcinoma de pulmón. |
EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
CA2957466C (en) | 2014-08-05 | 2023-10-17 | Exelixis, Inc. | Drug combinations to treat multiple myeloma |
WO2016061253A1 (en) | 2014-10-14 | 2016-04-21 | Exelixis, Inc. | Drug combination to treat melanoma |
-
2015
- 2015-08-05 CA CA2957466A patent/CA2957466C/en active Active
- 2015-08-05 WO PCT/US2015/043825 patent/WO2016022697A1/en active Application Filing
- 2015-08-05 MA MA040457A patent/MA40457A/fr unknown
- 2015-08-05 UA UAA201702039A patent/UA121482C2/uk unknown
- 2015-08-05 EP EP15750223.8A patent/EP3177311A1/en active Pending
- 2015-08-05 KR KR1020177006288A patent/KR102634247B1/ko active IP Right Grant
- 2015-08-05 EA EA201790312A patent/EA034992B1/ru not_active IP Right Cessation
- 2015-08-05 AU AU2015301097A patent/AU2015301097B2/en active Active
- 2015-08-05 MX MX2017001490A patent/MX2017001490A/es unknown
- 2015-08-05 US US15/501,582 patent/US11065240B2/en active Active
- 2015-08-05 BR BR112017002318-0A patent/BR112017002318A2/pt active Search and Examination
- 2015-08-05 JP JP2017506390A patent/JP6892381B2/ja active Active
- 2015-08-05 CN CN201580042010.4A patent/CN106573042A/zh active Pending
-
2019
- 2019-10-10 JP JP2019186703A patent/JP2020002179A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102812027A (zh) * | 2010-02-03 | 2012-12-05 | 因西特公司 | 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪 |
WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
CN103304552A (zh) * | 2012-03-09 | 2013-09-18 | 广东东阳光药业有限公司 | 取代的吡啶化合物及其使用方法和用途 |
Non-Patent Citations (4)
Title |
---|
CAÑADAS I ET AL: "C-MET as a new therapeutic target for the development of novel anticancer drugs", 《CLINICAL & TRANSLATIONAL ONCOLOGY》 * |
MILLIGAN SHAWN A ET AL: "The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non–small Cell Lung Cancer Cells", 《CLINICAL CANCER RESEARCH》 * |
MOSCHETTA MICHELE ET AL: "Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma", 《CLINICAL CANCER RESEARCH》 * |
WENZHONG QUE ET AL: "Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt⁄mTOR activity", 《APMIS》 * |
Also Published As
Publication number | Publication date |
---|---|
US20170224672A1 (en) | 2017-08-10 |
CA2957466C (en) | 2023-10-17 |
EP3177311A1 (en) | 2017-06-14 |
WO2016022697A1 (en) | 2016-02-11 |
BR112017002318A2 (pt) | 2018-07-17 |
EA201790312A1 (ru) | 2017-06-30 |
JP6892381B2 (ja) | 2021-06-23 |
MA40457A (fr) | 2017-06-14 |
MX2017001490A (es) | 2017-05-11 |
JP2017526662A (ja) | 2017-09-14 |
UA121482C2 (uk) | 2020-06-10 |
AU2015301097B2 (en) | 2021-03-04 |
KR20170031786A (ko) | 2017-03-21 |
AU2015301097A1 (en) | 2017-03-02 |
EA034992B1 (ru) | 2020-04-15 |
US11065240B2 (en) | 2021-07-20 |
JP2020002179A (ja) | 2020-01-09 |
KR102634247B1 (ko) | 2024-02-05 |
CA2957466A1 (en) | 2016-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106573042A (zh) | 治疗多发性骨髓瘤的药物组合 | |
CN104093398B (zh) | 7‑(6‑(2‑羟基丙烷‑2‑基)吡啶‑3‑基)‑1‑((反式)‑4‑甲氧基环己基)‑3,4‑二氢吡嗪并[2,3‑b]吡嗪‑2(1h)‑酮、其固体形式的药物组合物及其使用方法 | |
TW201904586A (zh) | (s)-2-乙基丁基2-(((s)-(((2r,3s,4r,5r) -5-(4-胺基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4-二羥基四氫呋喃-2-基)甲氧基)(苯氧基)磷醯基)胺基)丙酸酯之結晶形式 | |
TWI662962B (zh) | 治療癌症之方法 | |
WO2012174327A1 (en) | Combination therapies for treating hematologic malignancies using pyridopyrimidinone inhibitors of pi3k/mtor with bendamustine and/or rituximab | |
Chen et al. | Novel phthalide derivatives: Synthesis and anti-inflammatory activity in vitro and in vivo | |
WO2012065019A2 (en) | Pyridopyrimidinone inhibitors of p13k alpha | |
CN102351857A (zh) | 盐酸托烷司琼化合物 | |
US20230167116A1 (en) | Purine derivatives as sik-3 inhibitors | |
CN109982701A (zh) | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 | |
CN102367252A (zh) | 一种盐酸托烷司琼化合物 | |
CN110003204A (zh) | 一种bet蛋白抑制剂、其制备方法及用途 | |
CN116368141A (zh) | 噻二唑酮衍生物及其作为ampk激动剂用于治疗糖尿病和相关疾病的用途 | |
CN101361741A (zh) | 异噁唑啉类衍生物抗肿瘤新用途 | |
Li et al. | Novel O-benzylcinnamic acid derivative L26 treats acute lung injury in mice by MD-2 | |
CN111821303B (zh) | 沃替西汀及其盐在制备抗肿瘤药物中的应用 | |
BR112021013377A2 (pt) | Inibidores de lta4h para o tratamento de hidradenite supurativa | |
RU2603959C1 (ru) | ДИХЛОРАЦЕТАТ {3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-ПИРАЗОЛ-1-ИЛ]-1-ЭТИЛСУЛЬФОНИЛ-АЗЕТИДИН-3-ИЛ}-АЦЕТОНИТРИЛА В КАЧЕСТВЕ ИНГИБИТОРА ЯНУС КИНАЗ | |
CN101805355B (zh) | 一类噻吩并吡啶酮衍生物、其制备方法和用途 | |
US20220162214A1 (en) | Polymorphs of a Kinase Inhibitor, Pharmaceutical Compositions Containing Such a Compound, Preparation Methods, and Applications | |
US20230064254A1 (en) | Therapeutic agent containing fused pyrimidine compound as active ingredient | |
TW202425966A (zh) | 用於治療腫瘤的藥物組合、藥物組成物及其用途 | |
MAHALEKSHMI et al. | IN SILICO MOLECULAR SCREENING AND DOCKING APPROACHES ON ANTINEOPLASTIC AGENT-IRINOTECAN TOWARDS THE MARKER PROTEINS OF COLON CANCER | |
CA2848724A1 (en) | Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer | |
CN1990462A (zh) | 琥珀酰肼类化合物及其组合物在制备治疗抗白血病药物方面的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170419 |
|
RJ01 | Rejection of invention patent application after publication |